Generation Bio (NASDAQ:GBIO) Azioni

GENERATION BIO CO

Generation Bio

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Generation Bio Co

Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares dropped 24.2% to $3.35 on Friday after the company reported disappointing quarterly results and announced leadership changes.
What To Know: The semiconductor firm <a href="https://www.benzinga.com/pressreleases/25/05/b45299351/wolfspeed-reports-financial-results-for-the-third-quarter-of-fiscal-year-2025">posted</a> a non-GAAP loss of 72 cents per share, beating analyst expectations of a 77 cent loss, yet widening from last year's 62 cent loss. Quarterly revenue fell 7.6% year-over-year to $185.4 million, missing consensus estimates of $194.1 million.
Gross margins suffered due to underutilization costs tied to the ramp-up at its Mohawk Valley facility, which contributed $78 million in revenue—up from $28 million a year ago. GAAP gross margin fell to -12%, and non-GAAP gross margin dropped to 2%, reflecting continued pressure on profitability.
Despite financial setbacks, the company <a href="https://www.benzinga.com/news/earnings/25/05/45303071/wolfspeed-stock-slides-after-q3-revenues-miss-estimates-heres-what-to-know">highlighted</a> progress in strengthening its capital structure, including a $200 million ATM offering and nearly $192 million in tax refunds. Wolfspeed also <a href="https://www.benzinga.com/pressreleases/25/05/b45315250/wolfspeed-adds-two-seasoned-directors-to-its-board">appointed</a> Paul Walsh and Mark Jensen to its Board to support restructuring efforts. 
CEO Robert Feurle, who recently joined, emphasized the company's competitive edge in silicon carbide technology and its path to innovation. Longtime board member Stacy Smith announced he will not seek re-election.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/05/45317301/5-treasury-yields-could-force-trump-to-slash-tariffs-in-q2-says-bofas-hartnett">5% Treasury Yields Could Force Trump To Slash Tariffs In Q2, Says BofA&#8217;s Hartnett</a>
<h2 class="wp-block-heading">How To Buy WOLF Stock</h2>
By now you're likely curious about how to participate in the market for Wolfspeed &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Wolfspeed, which is trading at $4.43 as of publishing time, $100 would buy you 29.85 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WOLF has a 52-week high of $30.86 and a 52-week low of $2.06.

News

WOLF

Wolfspeed (WOLF) Stock Plummets Following Earnings Miss And Leadership Changes

Lake Street analyst Jacob Stephan maintains Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a Buy and raises the price target from $118 to $177.

Price Target

Analyst Ratings

DAVE

Lake Street Maintains Buy on Dave, Raises Price Target to $177

Piper Sandler analyst James Fish reiterates Akamai Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) with a Neutral and raises the price target from $80 to $88.

Reiteration

AKAM

Piper Sandler Reiterates Neutral on Akamai Technologies, Raises Price Target to $88

Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Overweight and raises the price target from $105 to $125.

TMDX

Piper Sandler Reiterates Overweight on TransMedics Group, Raises Price Target to $125

WIIM

VHI stock has given up its prior loss. Valhi shares were trading lower after the company reported worse-than-expected Q1 EPS results.

Shares of Nuvve Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) rallied <a href="https://www.benzinga.com/movers">on Friday </a>after the company partnered with several consultants specializing in blockchain strategy.
The consulting team will guide <a href="https://www.benzinga.com/pressreleases/25/05/b45316666/nuvve-engages-crypto-venture-group-to-accelerate-digital-asset-strategy">Nuvve in crafting a detailed strategy </a>for its cryptocurrency ventures via its digital asset treasury division, Nuvve-DigitalAssets.
Nuvve&#8217;s fully <a href="https://www.benzinga.com/news/25/04/45046313/nuvve-expands-beyond-evs-with-bold-bitcoin-crypto-investment-arm">owned subsidiary</a> aims to explore new possibilities within the blockchain space.
Although it recognizes prominent cryptocurrencies such as Bitcoin, Ethereum, and Solana, the company intends to concentrate its efforts on lesser-known digital assets linked to sectors like decentralized finance (DeFi), decentralized physical infrastructure (DePin), programming-related tokens, and the digitization of real-world assets.
Also Read: <a href="https://www.benzinga.com/25/05/45304751/evgos-strategic-positioning-brightens-growth-prospects-says-analyst">EVgo Is Well-Positioned For Robust Revenue Growth &#8211; Analyst</a>
&#8220;The companies that thrive in this new economy will be the ones who understand where finance is going and have the courage to move early,&#8221; said Chair of the committee James Altucher. &#8220;Nuvve is doing both with the right team and a clear strategy.&#8221;
To manage the initiative, the company is setting up a governance body, the Digital Asset Management Portfolio Committee. 
This oversight panel will be led by crypto investor and author James Altucher, joined by financial analyst Tim Collins and Gregory Poilasne, the company&#8217;s CEO.
Together, they will steer the investment approach to ensure systemic risk controls and value creation.
Nuvve plans to inform its investors by consistently sharing information on its digital asset portfolio and investment approach through the Nuvve-DigitalAssets platform.
The company facilitates transportation electrification with its vehicle-to-grid (V2G) technology, which allows electric vehicles to store and return energy to the grid. Nuvve aims to reduce EV ownership costs and promote a cleaner, more resilient energy system.
Price Action: NVVE shares traded higher by 93.86% at $2.21 at last check Friday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45295499/carvana-stock-jumps-q1-surpasses-expectations-says-analyst">Carvana Stock Jumps: Q1 Surpasses Expectations, Says Analyst</a></li>
</ul>
Image: Shutterstock

General

NVVE

Nuvve Taps Crypto Advisors To Fuel Digital Asset Subsidiary, Stock Soars

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) with a Neutral and lowers the price target from $80 to $78.

SOLV

Piper Sandler Maintains Neutral on Solventum, Lowers Price Target to $78

DA Davidson analyst Tom White maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and lowers the price target from $103 to $92.

DA Davidson Maintains Buy on Trade Desk, Lowers Price Target to $92

JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and raises the price target from $46 to $47.

CDTX

JMP Securities Maintains Market Outperform on Cidara Therapeutics, Raises Price Target to $47

Piper Sandler analyst Matt O'Brien maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Overweight and lowers the price target from $100 to $80.

GMED

Piper Sandler Maintains Overweight on Globus Medical, Lowers Price Target to $80

Trading Ideas

APUS

Apimeds Pharmaceuticals Shares Halted To The Downside

IPOs

Apimeds Pharmaceuticals IPO Shares Opened For Trade At $3.60/Share; IPO Priced At $4/Share On 3.375M Shares

DA Davidson analyst Gil Luria maintains JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) with a Buy and raises the price target from $40 to $45.

FROG

DA Davidson Maintains Buy on JFrog, Raises Price Target to $45

Piper Sandler analyst Matt O'Brien maintains CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) with a Overweight and lowers the price target from $20 to $12.

CVRX

Piper Sandler Maintains Overweight on CVRx, Lowers Price Target to $12

JMP Securities analyst David Scharf maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Market Outperform and lowers the price target from $85 to $75.

AFRM

JMP Securities Maintains Market Outperform on Affirm Holdings, Lowers Price Target to $75

EGHAU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

DA Davidson analyst Gil Luria maintains Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) with a Neutral and raises the price target from $28 to $35.

APPN

DA Davidson Maintains Neutral on Appian, Raises Price Target to $35

Rumors

ASTS

Watching AST SpaceMobile; Shares See A Small Pop In Volume, Traders Circulate Mentions Of Stock On Popular Newsletter

Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) with a Neutral and raises the price target from $36 to $37.

COLL

Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Raises Price Target to $37

DA Davidson analyst Linda Bolton Weiser maintains Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) with a Buy and lowers the price target from $13 to $7.

Comments

Generation Bio

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO